Newron Pharmaceuticals SpA, of Milan, Italy, said it completed a capital increase, raising gross proceeds of CHF24.3 million (US$25.5 million) following the subscription by institutional investors of 843,072 newly issued shares. The fundraising was supported by current institutional shareholders and institutional investors from Europe and the U.S., including Aviva, J.P. Morgan Asset Management, Investor AB, Sphera Global Healthcare Fund and Nyenburgh.